Precision BioSciences doses first patient in DMD gene-editing trial

August 24, 2026 6:01 AM

Precision BioSciences, Inc. (Nasdaq: DTIL) announced that it dosed the first patient in August in its Phase 1/2 FUNCTION-DMD clinical ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found